Meeting
2012 Gastrointestinal Cancers Symposium
Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer.
Authors
Geoffrey Yuyat Ku
Johns Hopkins Singapore International Medical Center, Singapore, Singapore
Geoffrey Yuyat Ku , Benjamin Haaland , Tatsuya Ioka , Hiroyuki Isayama , Yousuke Nakai , Ann-Lii Cheng , Takuji Okusaka , Gilberto de Lima Lopes Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 311)
DOI
10.1200/jco.2012.30.4_suppl.311
Abstract #
311
Poster Bd #
D33
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich